Cu-64 rituximab

Cu-64 rituximab, also known as 64Cu-DOTA-rituximab, is a radiopharmaceutical developed for positron emission tomography (PET) imaging of CD20-positive non-Hodgkin's lymphoma (NHL). This agent combines the targeting capabilities of rituximab, a chimeric murine/human monoclonal antibody that binds to CD20 antigen on B cells, with the radioactive copper-64 isotope for imaging purposes[1][4]. ## Development and Mechanism 64Cu-DOTA-rituximab was developed to create a PET imaging agent that can monitor the treatment of NHL[1]. The drug works by specifically binding to CD20, which is expressed on B-cell lymphomas. The radioactive copper-64 isotope allows for visualization of CD20-positive cells through PET imaging[3][5]. Studies have shown that 64Cu-DOTA-rituximab uptake in lymph nodes associated with lymphoma progressively increases from 1 to 48 hours after injection, while uptake in normal organs generally decreases over time (except in liver and spleen)[3]. The specificity of this agent has been demonstrated in studies showing that binding to CD20-positive Raji cells was 90 times higher than to CD20-negative Jurkat cells[3]. ## Clinical Applications The primary application of 64Cu-DOTA-rituximab is for targeted imaging of CD20-positive lymphomas. This imaging approach could potentially be used to: 1. Select appropriate patients for rituximab treatment 2. Monitor treatment response 3. Guide advanced radioimmunotherapy approaches, such as alpha particle therapy[5] Research has shown that 64Cu-DOTA-rituximab PET/CT demonstrates higher SUVmax in tumors (18.1 ± 8.3) compared to standard 18F-FDG PET/CT (5.2 ± 1.5), as well as higher tumor-to-background ratios (55.7 ± 31.0 vs 8.6 ± 2.8)[3]. This suggests improved diagnostic capabilities for detecting CD20-positive lymphoma lesions. ## Safety Profile No adverse events related to 64Cu-DOTA-rituximab injection were reported in the studies mentioned in the search results[3]. The predicted human effective dose for administration of 64Cu-DOTA-rituximab was measured as 1.07E-02 mSv/MBq[3]. ## Development Status 64Cu-DOTA-rituximab appears to be in investigational stages, with studies demonstrating its feasibility for targeted imaging of CD20-positive lymphomas. The search results indicate it was initially developed by Stanford University[3]. While the FDA has granted Fast Track Designation for other copper-64 radiopharmaceuticals like 64Cu-SAR-bisPSMA for prostate cancer imaging[6][8], there is no specific mention of regulatory status for 64Cu-DOTA-rituximab in the provided search results.

Other names

64Cu-DOTA-rituximab